Moderna Stock Price Surges 50% on Positive Clinical Trial Results

Moderna stock (MRNA) has entered a pivotal moment, with its daily chart remaining firmly bullish despite some intraday volatility. On August 19, the company and Merck announced positive Phase 3 INTerpath-001 results, which triggered headlines of a 50% surge in Moderna's stock price.

The daily chart shows that the close on August 18 was above the EMA20, EMA50, and EMA200 levels. The RSI14 is at 55.04, leaving room for further upside without immediate exhaustion risk. Momentum has been building steadily, with the MACD line sitting above its signal line.

However, the hourly timeframe shows a brief pullback, with price slipping below the EMA20 while remaining above the EMA50 and EMA200. The RSI14 on this timeframe reads 46.62, a neutral level reflecting the pause rather than aggressive selling.

The 15-minute chart shows short-term weakness near support, but this is mostly execution-level noise relative to the daily trend. Given the daily ATR14 of 3.76 and the scale of the reported price reaction, volatility around Moderna stock is likely to remain elevated in the sessions ahead.